{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:00:04Z","timestamp":1767992404594,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shijiazhuang Pharmaceutical Group Pharmaceutical Co. Ltd."},{"name":"Xi\u2019an International Medical Center Hospital Hospital Level Project","award":["NO.2020ZD007"],"award-info":[{"award-number":["NO.2020ZD007"]}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["NO.2019JQ-251"],"award-info":[{"award-number":["NO.2019JQ-251"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>As one of the leading causes of morbidity and mortality, stroke and its recurrence has attracted more and more attention. Dl-3-n-butylphthalidle(NBP) has been widely used for treating acute ischemic stroke in China and shows a great clinical effect. NBP plays a role in different pathophysiological processes in the treatment of ischemic stroke, including antioxidants, anti-inflammatory, anti-apoptotic, anti-thrombosis, and mitochondrial protection. Many randomized, double-blind, placebo-controlled, multicenter clinical trials suggest that NBP is a safe and effective treatment for ischemic stroke. To sum up, the current research is mainly focused on the short-term treatment of stroke patients with RCT (randomized controlled trial). Therefore, we designed this study to confirm the role of butylphthalide in secondary stroke prevention in the real world.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study will be a multicenter, prospective real-world trial. We would recruit 8000 patients with ischemic stroke from 78 public hospitals in China. All participants will be allocated to one of two parallel treatment groups according to their own wills: (1) butylphthalide group: 0.2\u00a0g of butylphthalide capsules three times daily plus routine treatment (aspirin 50-300\u00a0mg\/d, clopidogrel 75\u00a0mg\/d, etc.); (2) control group: routine treatment (aspirin 50-300\u00a0mg\/d, clopidogrel 75\u00a0mg\/d, etc.). Treatment duration is 90 consecutive days or more. The primary outcome is recurrence rate of stroke within 1\u00a0month, 3\u00a0months, 6\u00a0months and 1\u00a0year in butylphthalide group and control group. The secondary outcomes included NIHSS score, the mRS score, other clinical cardiovascular events within one year (sudden death \/ myocardial infarction \/ arrhythmia \/ heart failure, etc.), and adverse events of patients in groups. NIHSS will be captured in the first month after discharge, and the others will be captured at the same time points as the primary end point.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This trial will be exploring the efficacy and safety of butylphthalide in secondary prevention of ischemic stroke to expand the scope of application of butylphthalide soft capsules and provide new ideas for enriching the secondary prevention of stroke.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Chinese Clinical Trial Registry (ChiCTR). Trial registration number: ChiCTR2000034481. Registered on 6 July 2020,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=55800\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj=55800<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-022-02815-x","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:03:58Z","timestamp":1660896238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet"],"prefix":"10.1186","volume":"22","author":[{"given":"Junchao","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"04","key":"2815_CR1","first-page":"P281","volume":"38","author":"National Health Commission Emergency Medical quality Control Center","year":"2018","unstructured":"National Health Commission Emergency Medical quality Control Center. Expert consensus on emergency diagnosis and treatment of acute ischemic stroke in China. Chin J Critical Care Med. 2018;38(04):P281-287.","journal-title":"Chin J Critical Care Med"},{"issue":"4","key":"2815_CR2","first-page":"217","volume":"14","author":"W Longde","year":"2017","unstructured":"Longde W, Jinhuan W, Bin P, et al. Summary of China Stroke Prevention and treatment report 2016. Chin J Cerebrovascular Dis. 2017;14(4):217\u201324.","journal-title":"Chin J Cerebrovascular Dis"},{"key":"2815_CR3","unstructured":"Benjamin EJ, Muntner P, Alonso A. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e28."},{"issue":"12","key":"2815_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/CM9.0000000000000289","volume":"132","author":"XQ Chen","year":"2019","unstructured":"Chen XQ, Qiu K, Liu H, Lu W. Application and prospects of butylphthalide for the treatment of neurologic diseases. Chin Med J (Engl). 2019;132(12):1467\u201377.","journal-title":"Chin Med J (Engl)"},{"issue":"06","key":"2815_CR5","first-page":"460","volume":"56","author":"Cerebral blood flow and metabolism Branch of Chinese Stroke Society","year":"2017","unstructured":"Cerebral blood flow and metabolism Branch of Chinese Stroke Society. Chinese Guidelines for collateral circulation assessment and intervention in ischemic stroke (2017). Chin J Internal Med. 2017;56(06):460\u201371.","journal-title":"Chin J Internal Med"},{"issue":"3","key":"2815_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1142\/S0192415X19500265","volume":"47","author":"ZQ Xu","year":"2019","unstructured":"Xu ZQ, Zhou Y, Shao BZ, Liu C, et al. A systematic review of neuroprotective efficacy and safety of DL-3-N-Butylphthalide in ischemic stroke. Am J ChinMed. 2019;47(3):507\u201325.","journal-title":"Am J ChinMed"},{"issue":"30","key":"2815_CR7","doi-asserted-by":"publisher","first-page":"e7257","DOI":"10.1097\/MD.0000000000007257","volume":"96","author":"C Zhang","year":"2017","unstructured":"Zhang C, Zhao S, Zang Y, Zhang C, et al. The efficacy and safety of Dl-3n-butylphthalide on progressive cerebral infarction A randomized controlled STROBE study. Medicine (Baltimore). 2017;96(30):e7257.","journal-title":"Medicine (Baltimore)"},{"key":"2815_CR8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3892\/etm.2016.3139","volume":"11","author":"LX Xue","year":"2016","unstructured":"Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H. Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke. Exp Ther Med. 2016;11:2015\u201320.","journal-title":"Exp Ther Med"},{"key":"2815_CR9","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3760\/cma.j.issn.0366-6999.20123240","volume":"126","author":"LY Cui","year":"2013","unstructured":"Cui LY, Zhu YC, Gao S, et al. Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: A randomized, double-blind trial. Chin Med J (Engl). 2013;126:3405\u201310.","journal-title":"Chin Med J (Engl)"},{"key":"2815_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.018","volume":"25","author":"H Zhao","year":"2016","unstructured":"Zhao H, Yun W, Zhang Q, et al. Mobilization of circulating endo-thelial progenitor cells by dl-3-n-butylphthalide in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2016;25:752\u201360.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2815_CR11","first-page":"796","volume":"24","author":"Q Chang","year":"2003","unstructured":"Chang Q, Wang XL. Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin. 2003;24:796\u2013804.","journal-title":"Acta Pharmacol Sin"},{"key":"2815_CR12","first-page":"896","volume":"30","author":"XG Liu","year":"1995","unstructured":"Liu XG, Feng YP. Protective effect of dl-3-n-butylphthalide on ischemic neurological damage and abnormal behavior in rats subjected to focal ischemia. Yao Xue Xue Bao. 1995;30:896\u2013903.","journal-title":"Yao Xue Xue Bao"},{"key":"2815_CR13","first-page":"102","volume":"12","author":"W Deng","year":"1997","unstructured":"Deng W, Feng Y. Effect of dl-3-n-butylphthalide on brain edema in rats subjected to focal cerebral ischemia. Chin Med Sci J. 1997;12:102\u20136.","journal-title":"Chin Med Sci J"},{"key":"2815_CR14","first-page":"696","volume":"20","author":"ZZ Chong","year":"1999","unstructured":"Chong ZZ, Feng YP. Dl-3-n-butylphthalide attenuates reperfusion-induced blood\u2013brain barrier damage after focal cerebral ischemia in rats. Zhongguo Yao Li Xue Bao. 1999;20:696\u2013700.","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"2815_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1124\/jpet.105.098517","volume":"317","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Wang L, Li J, Wang XL. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther. 2006;317:973\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"2815_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fphar.2016.00394","volume":"7","author":"M Bi","year":"2016","unstructured":"Bi M, Zhang M, Guo D, Bi W, Liu B, Zou Y, Li Q. N-butylphthalide alleviates blood\u2013brain barrier impairment in rats exposed to carbon monoxide. Front Pharmacol. 2016;7:394.","journal-title":"Front Pharmacol"},{"key":"2815_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bmcl.2017.01.050","volume":"27","author":"X Qiang","year":"2017","unstructured":"Qiang X, Li Y, Yang X, Luo L, Xu R, Zheng Y, Cao Z, Tan Z, Deng Y. DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-beta aggregation and monoamine oxidases with high antioxidant potency for Alzheimer\u2019s therapy. Bioorg Med Chem Lett. 2017;27:718\u201322.","journal-title":"Bioorg Med Chem Lett"},{"key":"2815_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jns.2007.04.025","volume":"260","author":"CL Liu","year":"2007","unstructured":"Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX, Xie LC, et al. dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP. J Neurol Sci. 2007;260:106\u201313. https:\/\/doi.org\/10.1016\/j.jns.2007.04.025.","journal-title":"J Neurol Sci"},{"key":"2815_CR19","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.neuropharm.2012.02.014","volume":"62","author":"J Xu","year":"2012","unstructured":"Xu J, Wang Y, Li N, Xu L, Yang H, Yang Z. L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia. Neuropharmacology. 2012;62:2424\u20139. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.02.014.","journal-title":"Neuropharmacology"},{"issue":"5","key":"2815_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/1871527317666180612125843","volume":"17","author":"S Wang","year":"2018","unstructured":"Wang S, Ma F, Huang L, Peng Y, et al. Dl-3-n-Butylphthalide (NBP): a promising therapeutic agent for ischemic stroke. CNS Neurol Disord Drug Targets. 2018;17(5):338\u201347.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2815_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S1875-5364(17)30021-3","volume":"14","author":"XL Wang","year":"2016","unstructured":"Wang XL, Wang ZY, Ling JJ, Zhang YH, Yin J. Synthesis and biological evaluation of nitric oxide (NO)-hydrogen sulfide (H2S) releasing derivatives of (S)-3-nbutylphthalide as potential antiplatelet agents. Chin J Nat Med. 2016;14:946\u201353. https:\/\/doi.org\/10.1016\/S1875-5364(17)30021-3.","journal-title":"Chin J Nat Med"},{"key":"2815_CR22","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1080\/14786419.2015.1136907","volume":"30","author":"M Chen","year":"2016","unstructured":"Chen M, Liu Q, Tan M, Wen S, Pi R, Lin D. Synthesis and biological evaluation of n-butylphthalide derivatives as anti-platelet aggregation agents. Nat Prod Res. 2016;30:2716\u20139. https:\/\/doi.org\/10.1080\/14786419.2015.1136907.","journal-title":"Nat Prod Res"},{"key":"2815_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2009.06.018","volume":"1289","author":"SJ Liao","year":"2009","unstructured":"Liao SJ, Lin JW, Pei Z, Liu CL, Zeng JS, Huang RX. Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP. Brain Res. 2009;1289:69\u201378. https:\/\/doi.org\/10.1016\/j.brainres.2009.06.018.","journal-title":"Brain Res"},{"key":"2815_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.018","volume":"25","author":"H Zhao","year":"2016","unstructured":"Zhao H, Yun W, Zhang Q, Cai X, Li X, Hui G, et al. Mobilization of circulating endothelial progenitor cells by dl-3-n-butylphthalide in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2016;25:752\u201360. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2015.11.018.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2815_CR25","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1016\/j.bmcl.2015.06.090","volume":"25","author":"X Sheng","year":"2015","unstructured":"Sheng X, Hua K, Yang C, Wang X, Ji H, Xu J, Huang Z, Zhang Y. Novel hybrids of 3-nbutylphthalide and edaravone: design, synthesis and evaluations as potential anti-ischemic stroke agents. Bioorg Med Chem Lett. 2015;25:3535\u201340.","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"2815_CR26","first-page":"3","volume":"6","author":"C Liying","year":"2006","unstructured":"Liying C, Shunwei Li. Dl-3-n-butylphthalide in the treatment of acute ischemic stroke: a randomized double-blind controlled study. Chin J Modern Neurological Dis. 2006;6(4):3.","journal-title":"Chin J Modern Neurological Dis"},{"key":"2815_CR27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.018","volume":"25","author":"H Zhao","year":"2016","unstructured":"Zhao H, Yun W, Zhang Q, Cai X, Li X, Hui G, et al. Mobilization of circulating endothelial progenitor cells by dl-3-n-butylphthalide in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2016;25:752.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2815_CR28","first-page":"666","volume":"09","author":"B Peng","year":"2016","unstructured":"Peng B, Wu B. Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018. Chin J Neurol. 2016;09:666\u201382.","journal-title":"Chin J Neurol"},{"issue":"12","key":"2815_CR29","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1161\/01.STR.0000098902.69855.A9","volume":"34","author":"CS Kidwell","year":"2004","unstructured":"Kidwell CS, Warach S. Acute ischemic cerebrovascular syndrome diagnostic criteria. Stroke. 2004;34(12):2995\u20138.","journal-title":"Stroke"},{"key":"2815_CR30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1161\/01.str.32.4.866","volume":"32","author":"R Handschu","year":"2001","unstructured":"Handschu R, Garling A, Heuschmann PU, Kolominsky-Rabas PL, Erbguth F, Neund\u00f6rfer B. Acute stroke management in the local general hospital. Stroke. 2001;32:866\u201370. https:\/\/doi.org\/10.1161\/01.str.32.4.866.","journal-title":"Stroke"},{"key":"2815_CR31","unstructured":"National Medical Products Administration: Circular of the State Drug Administration on guidelines for the publication of realworld evidence in support of drug development and review (for trial implementation) (No.1 of 2020) http:\/\/www.nmpa.gov.cn\/WS04\/CL2138\/373175.html. Accessed 3 Jan 2020."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02815-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02815-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02815-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:37:52Z","timestamp":1727836672000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02815-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02815-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"24 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been reviewed and approved by the Medical Ethics Committee of Northwestern University of China(XDLL2020042). Written, informed consent to participate will be obtained from all participants.Informed consent form can be found in supplementary material.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"305"}}